Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLI-1008
- Development stage
- Unknown
- Lead developer
- BioLite
- Administration
- Oral
01
Overview
BLI-1008 is an investigational botanical drug candidate being developed by BioLite for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a botanical drug, it is derived from plant materials and is designed to address the core symptoms of ADHD, such as inattention and hyperactivity, through the modulation of neurophysiological pathways. The candidate is part of BioLite's CNS-focused pipeline, which emphasizes the development of standardized botanical extracts with potentially improved safety profiles compared to traditional stimulant medications. BLI-1008 has progressed into Phase II clinical development to evaluate its efficacy and safety in managing ADHD symptoms.
02
Targets
NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on BLI-1008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BLI-1008.